Episode

Episode 204 - Samir Ounzain - Co-founder & CEO Haya Therapeutics

Podcast
The BioHub - by Avetix
Published
Jul 20, 2026
Duration seconds
1740
Processing state
not_requested
Canonical source
https://podcasters.spotify.com/pod/show/max-brennan4/episodes/Episode-204---Samir-Ounzain---Co-founder--CEO-Haya-Therapeutics-e3mac0f
Audio
https://anchor.fm/s/f0076084/podcast/play/123071951/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2026-6-20%2F428278780-44100-2-8aa25eeb10475.mp3
JSON
/v1/public/podcasts/the-biohub-by-avetix-7252289/episodes/episode-204-samir-ounzain-co-founder-ceo-haya-therapeutics
Markdown
/podcast/the-biohub-by-avetix-7252289/episode-204-samir-ounzain-co-founder-ceo-haya-therapeutics.md

Actions

  • POST https://stenobird.com/v1/public/podcasts/the-biohub-by-avetix-7252289/episodes/episode-204-samir-ounzain-co-founder-ceo-haya-therapeutics/transcription-requests
    Idempotently request low-priority transcript generation for this episode.
  • GET https://stenobird.com/podcast/the-biohub-by-avetix-7252289/episode-204-samir-ounzain-co-founder-ceo-haya-therapeutics.md
    Read the agent-friendly Markdown representation of this episode resource.

Summary

In this episode of The BioHub by Avetix, I'm joined by Samir Ounzain , CEO and Co-Founder of HAYA Therapeutics . Samir shares the journey from pioneering research into the so-called "dark genome" to building one of biotech's most exciting RNA therapeutics companies. We discuss why long non-coding RNAs could unlock an entirely new class of precision medicines, the challenge of turning groundbreaking science into a business, and how HAYA is approaching diseases with significant unmet need. We also explore the importance of resilience in biotech, the evolution from scientist to CEO, the role AI is beginning to play in drug discovery, and what the future holds for RNA therapeutics and precision medicine.